Feedback
Settings

Settings

Goto Application

3,957 results
Offices all Languages Stemming false Single Family Member true Include NPL false

Save query

A private query is only visible to you when you are logged-in and can not be used in RSS feeds

Query Tree

Refine Options

Offices
All
Specify the language of your search keywords
Stemming reduces inflected words to their stem or root form.
For example the words fishing, fished,fish, and fisher are reduced to the root word,fish,
so a search for fisher returns all the different variations
Returns only one member of a family of patents
Include Non-Patent literature in results

Full Query

IC_EX:A61K39/42

Side-by-side view shortcuts

General
Go to Search input
CTRL + SHIFT +
Go to Results (selected record)
CTRL + SHIFT +
Go to Detail (selected tab)
CTRL + SHIFT +
Go to Next page
CTRL +
Go to Previous page
CTRL +
Results (First, do 'Go to Results')
Go to Next record / image
/
Go to Previous record / image
/
Scroll Up
Page Up
Scroll Down
Page Down
Scroll to Top
CTRL + Home
Scroll to Bottom
CTRL + End
Detail (First, do 'Go to Detail')
Go to Next tab
Go to Previous tab

Analysis

1 / 396
1.WO/2021/087015ENGINEERED ANTIBODIES TO HIV ENV
WO - 06.05.2021
Int.Class A61K 39/42
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
39Medicinal preparations containing antigens or antibodies
395Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
42viral
 Appl.No PCT/US2020/057816 Applicant INTERNATIONAL AIDS VACCINE INITIATIVE Inventor SOK, Devin
The present disclosure relates to anti-HIV Env antibodies and their use in the treatment or prevention of HIV/AIDS. In one aspect, provided herein are enhanced engineered anti-HIV Env antibodies that were derived from the PGDM1400 parent antibody using directed-evolution and yeast display. In one aspect, provided herein are pharmaceutical compositions comprising the enhanced engineered anti-HIV Env antibodies disclosed herein.
2.WO/2021/083409ANTI-CD97 MONOCLONAL ANTIBODY, VARIABLE REGION AND CONSTANT REGION SEQUENCES THEREOF, AND ANTI-BRAIN TUMOR APPLICATION
WO - 06.05.2021
Int.Class C07K 16/08
CCHEMISTRY; METALLURGY
07ORGANIC CHEMISTRY
KPEPTIDES
16Immunoglobulins, e.g. monoclonal or polyclonal antibodies
08against material from viruses
 Appl.No PCT/CN2020/137694 Applicant HENAN UNIVERSITY Inventor YIN, Jinlong
An anti-CD97 monoclonal antibody, variable region and constant region sequences thereof, and application thereof. The variable region sequences of the anti-CD97 monoclonal antibody comprise nucleotide sequences such as a heavy chain sequence as represented by SEQ ID NO: 1 and a light chain sequence as represented by SEQ ID NO: 2. The anti-CD97 monoclonal antibody prepared with the variable region sequences is able to bind specifically to CD97, and may be used in the preparation of medication for treating diseases (such as brain tumor) related to excessive or uncontrolled expression of CD97.
3.WO/2021/084064SEQUENTIAL ANTI-CD19 THERAPY
WO - 06.05.2021
Int.Class A61K 39/40
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
39Medicinal preparations containing antigens or antibodies
395Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
40bacterial
 Appl.No PCT/EP2020/080502 Applicant MORPHOSYS AG Inventor ENDELL, Jan
48 Abstract The present invention relates to therapeutic compositions and methods for sequential treatment of cancer in human patients using therapeutic agents that bind to human CD1g.
4.WO/2021/086899ANTI-HEMAGGLUTININ ANTIBODIES AND METHODS OF USE THEREOF
WO - 06.05.2021
Int.Class C07K 16/10
CCHEMISTRY; METALLURGY
07ORGANIC CHEMISTRY
KPEPTIDES
16Immunoglobulins, e.g. monoclonal or polyclonal antibodies
08against material from viruses
10from RNA viruses
 Appl.No PCT/US2020/057635 Applicant REGENERON PHARMACEUTICALS, INC. Inventor BAUM, Alina
Provided herein are monoclonal antibodies, or antigen-binding fragments thereof, that bind to the influenza B hemagglutinin (HA) protein, pharmaceutical compositions comprising the antibodies and methods of use. The antibodies are useful for inhibiting or neutralizing influenza B virus activity, thus providing a means of treating or preventing influenza infection in humans. Also provided is the use of one or more antibodies that bind to the influenza B HA for preventing viral attachment and/or entry into host cells. The antibodies may be used prophylactically or therapeutically and may be used alone or in combination with one or more other anti-viral agents or vaccines.
5.WO/2021/076559HUMAN BROADLY NEUTRALIZING ANTIBODIES AGAINST THE MEMBRANE-PROXIMAL EXTERNAL REGION OF HIV ENV FOR VACCINE DESIGN AND INTERVENTION
WO - 22.04.2021
Int.Class C07K 16/10
CCHEMISTRY; METALLURGY
07ORGANIC CHEMISTRY
KPEPTIDES
16Immunoglobulins, e.g. monoclonal or polyclonal antibodies
08against material from viruses
10from RNA viruses
 Appl.No PCT/US2020/055486 Applicant THE SCRIPPS RESEARCH INSTITUTE Inventor ZWICK, Michael
The present disclosure relates to anti-HIV antibodies and their use in the treatment or prevention of HIV/AIDS and in the development of HIV vaccines.
6.20210115114ANTIBODIES THAT NEUTRALIZE RSV, MPV AND PVM AND USES THEREOF
US - 22.04.2021
Int.Class C07K 16/10
CCHEMISTRY; METALLURGY
07ORGANIC CHEMISTRY
KPEPTIDES
16Immunoglobulins, e.g. monoclonal or polyclonal antibodies
08against material from viruses
10from RNA viruses
 Appl.No 16885009 Applicant Humabs BioMed SA Inventor Davide CORTI

The invention relates to antibodies, and antigen binding fragments thereof, that neutralize infection of both RSV, MPV and PVM. The invention also relates to nucleic acids that encode, immortalized B cells and cultured plasma cells that produce, and to polypeptides that bind to such antibodies and antibody fragments. In addition, the invention relates to the use of the antibodies, antibody fragments, and polypeptides recognized by the antibodies of the invention in screening methods as well as in the diagnosis, treatment and prevention of RSV or MPV infection and RSV and MPV co-infection.

7.112661841一种中和新冠病毒新表位的全人单克隆抗体17-2及其应用
CN - 16.04.2021
Int.Class C07K 16/10
CCHEMISTRY; METALLURGY
07ORGANIC CHEMISTRY
KPEPTIDES
16Immunoglobulins, e.g. monoclonal or polyclonal antibodies
08against material from viruses
10from RNA viruses
 Appl.No 202011406812.8 Applicant 广州市第八人民医院 Inventor 庾蕾
本发明属于生物技术领域，具体涉及一种中和新冠病毒新表位的全人单克隆抗体17‑2及其应用。本发明通过B细胞培养及单克隆抗体技术，成功筛选出针对S2的中和抗体17‑2。本发明提供的抗体17‑2，可与S蛋白及S2结合，其EC50分别为0.034μg/ml和0.038μg/mL，可有效中和SARS‑CoV‑2病毒。与其它表位的S1‑RBD和S1‑NTD抗体联合应用于SARS‑CoV‑2感染的预防和治疗。
8.112646005多肽、多肽疫苗及应用
CN - 13.04.2021
Int.Class C07K 14/165
CCHEMISTRY; METALLURGY
07ORGANIC CHEMISTRY
KPEPTIDES
14Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
005from viruses
08RNA viruses
165Coronaviridae, e.g. avian infectious bronchitis virus
 Appl.No 202011625769.4 Applicant 珠海碳云智能科技有限公司 Inventor 王健
本发明提供了多肽、多肽疫苗、抗原表位的筛选方法及应用。其中，多肽为SEQ ID NO：1至SEQ ID NO：154，尤其是SEQ ID NO：1至SEQ ID NO：40所示的40条肽段。通过创新性地结合多肽芯片技术筛选获得40条与冠状病毒感染，尤其是SARS‑Cov‑2病毒感染特异性相关的多肽，这些多肽能够被用来制备多肽疫苗、核酸疫苗、蛋白重组疫苗等相关疫苗产品，从而为防控此类病毒的传染和流行提供更有力的工具。
9.112626089一种SARS-CoV-2病毒S蛋白受体结合区域编码基因、抗体及应用
CN - 09.04.2021
Int.Class C12N 15/50
CCHEMISTRY; METALLURGY
12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
15Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
09Recombinant DNA-technology
11DNA or RNA fragments; Modified forms thereof
31Genes encoding microbial proteins, e.g. enterotoxins
33Genes encoding viral proteins
40Proteins from RNA viruses, e.g. flaviviruses
50Coronaviridae, e.g. infectious bronchitis virus, transmissible gastroenteritis virus
 Appl.No 202011445642.4 Applicant 杭州百凌生物科技有限公司 Inventor 潘丽
本发明公开了一种SARS‑CoV‑2病毒S蛋白受体结合区域编码基因表达的重组蛋白、其产生的抗体及应用，属于生物医学领域及免疫学检测领域。所述编码基因具有SEQ ID NO：2所示的核苷酸序列。所述编码基因或抗体可应用于制备检测抗SARS‑CoV‑2病毒S蛋白受体结合区域抗体。本发明公开了利用所述编码基因表达的重组蛋白制备的抗体及其应用。本发明的编码基因保证了蛋白表达的唯一性，减少了蛋白后续纯化的难度。制备的抗体检测抗原的灵敏度高、特异性强。
10.112625136针对冠状病毒具有中和活性的双特异性抗体及其用途
CN - 09.04.2021
Int.Class C07K 16/46
CCHEMISTRY; METALLURGY
07ORGANIC CHEMISTRY
KPEPTIDES
16Immunoglobulins, e.g. monoclonal or polyclonal antibodies
46Hybrid immunoglobulins
 Appl.No 202011300574.2 Applicant 三优生物医药（上海）有限公司 Inventor 郎国竣
本公开涉及针对冠状病毒具有中和活性的双特异性抗体及其用途，提供针对冠状病毒S蛋白并阻断其与ACE2受体结合的中和抗体来预防和治疗冠状病毒。具体涉及特异性结合冠状病毒S蛋白的抗体或多肽复合物，其包含(a)第一表位结合部分，包含重链可变区VH和轻链可变区VL，其中VH和VL形成特异性结合S蛋白的第一表位的抗原结合结构域，和(b)第二表位结合部分，包含特异性结合S蛋白的第二表位的单域抗体或其VHH片段，第一、第二表位结合部分彼此融合且互不相同。还涉及编码抗体或多肽复合物的多核苷酸及包含其的宿主细胞、制备抗体或多肽复合物的方法。所述抗体或多肽复合物可用于预防、治疗、诊断和/或检测冠状病毒。
# -